Pediatric cancer research: Surviving COVID-19

Research output: Contribution to journalArticlepeer-review


  • Jeffery J. Auletta
  • Peter C. Adamson
  • Jonathan E. Agin
  • Scott Kennedy
  • Mark W. Kieran
  • Donna M. Ludwinski
  • Leona J. Knox
  • Kristi McKay
  • Pia Rhiner
  • Carol J. Thiele
  • Timothy P. Cripe

Colleges, School and Institutes

External organisations

  • Ohio State University College of Medicine
  • National Cancer Institute
  • Bristol Myers Squibb
  • The Ohio State University
  • Nationwide Children's Hospital
  • Max Cure Foundation
  • European Society for Paediatric Oncology
  • Sanofi
  • Cancer Hospital


© 2020 Wiley Periodicals, Inc. A diverse panel of pediatric cancer advocates and experts, whose collective experience spans the continuum of international academic medicine, industry, government research, and cancer advocacy, recently discussed challenges for pediatric cancer research in the context of coronavirus disease 2019 (COVID-19). Specifically, this special report addresses the following focus areas: (a) the critical role that translational research has played in transforming pediatric cancer outcomes; (b) the current and potential future impact of COVID-19 on pediatric cancer research; (c) target areas of COVID-19 research that may have application in immunity, oncogenesis, and therapeutic discovery; and (d) future considerations and directions in maintaining pediatric cancer research during and after COVID-19.


Original languageEnglish
Pages (from-to)e28435
JournalPediatric Blood & Cancer
Publication statusPublished - 18 Jun 2020


  • advocacy, cancer, coronavirus, COVID-19, inflammation, pediatrics, relapse, research, systemic acute respiratory syndrome, tumor